Tactile Systems Technology's Q1 2024 financial results show a small miss on EPS but a strong beat on revenue, reflecting a 3.9% YoY increase.

For the full year 2025, CFO Birkemeyer reported, "we now expect total revenue in the range of $310 million to $315 million, representing growth of approximately 6% to 8% year-over-year." The guidance ...

Tactile Medical reports Q1 2025 results with slight revenue growth, increased gross margin, and a higher net loss compared to Q1 2024. Tactile Systems Technology, Inc. reported its financial results ...

Tactile Medical will release Q1 fiscal 2025 financial results on May 5, 2025, with a conference call at 5 PM ET. Tactile Systems Technology, Inc. announced that it will release its first quarter ...

Reports Q4 revenue $85.6M, consensus $85.39M. “Our fourth quarter results capped off a dynamic year for Tactile, during which we launched our next-generation lymphedema platform, generated clinical ...

The Company expects full year 2025 total revenue in the range of $316 million to $322 million, representing growth of approximately 8% to 10% year-over-year, compared to total revenue of $293.0 ...

Tactile Medical's fourth-quarter 2023 revenue grew 5% year over year to $77.7 million, translating to adjusted (non-GAAP) net income of $8.9 million, or $0.37 per share. Analysts, on average, were ...

The average one-year price target for Tactile Systems Technology (NasdaqGM:TCMD) has been revised to $30.34 / share. This is ...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage ...

MINNEAPOLIS, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment ...